- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tigulixostat lowers uric acid levels in gout patients with hyperuricemia: Study
![Tigulixostat lowers uric acid levels in gout patients with hyperuricemia: Study Tigulixostat lowers uric acid levels in gout patients with hyperuricemia: Study](https://medicaldialogues.in/h-upload/2020/05/14/750x450_128756-gout.webp)
USA: Tigulixostat significantly lowers the levels of serum uric acid (sUA) in gout patients with hyperuricemia versus placebo at all dose levels, according to results from a phase 2, dose-finding study. Also, the sUA lowering effect of tigulixostat appeared to be dose-dependent. Study participants tolerated well to the treatment with tigulixostat at all 3 dose levels.
The study was presented as the late-breaking posters at the ACR (American College of Rheumatology) Convergence 2021.
Gout, a form of arthritis, can be effectively managed by inhibiting uric acid synthesis. Tigulixostat, a novel non-purine selective xanthine oxidase inhibitor, lowers uric acid production and is shown to be well tolerated up to the maximum dose of 800 mg/day for seven-day administration in healthy subjects in a first-in-human clinical study.
Robert Terkeltaub, Professor of Medicine at the University of California, San Diego and Chief of Rheumatology at the VA Medical Center in San Diego, and colleagues conducted this phase 2 study in the US to assess the safety and efficacy of tigulixostat in gout patients with hyperuricemia and to find the appropriate doses for further development.
The study included gout patients with serum uric acid (sUA) ≥8.0 mg/dL to ≤12.0 mg/dL after a wash-out/prophylaxis period. They were randomized to one of tigulixostat 50 mg (n=34), 100 mg (n=38), 200 mg (n=37), or placebo groups (n=34) and received the study treatment, once-daily oral intake, for 12 weeks. The participants took colchicine 0.6 mg once daily as a gout flare prophylaxis from the screening period and until the end of the treatment.
The primary endpoint was the proportion of the subjects achieving sUA < 5 mg/dL at week 12.
Based on the study, the researchers found the following:
- Differences in the proportion to the placebo group were statistically significant at all tigulixostat dose levels at both sUA levels.
- The superiority of tigulixostat groups over the placebo group was demonstrated in the primary endpoint.
- Tigulixostat rapidly lowered sUA within 2 weeks from treatment initiation, and the sUA levels were well maintained throughout the study treatment period.
- Mean of maximum percent reduction in sUA was -46.67%, -50.64% and -66.79% and -11.20, respectively.
- Total 12.9%, 13.16%, 10.81%, and 9.38% of the subjects had gout flares that required rescue treatment, respectively.
- TEAEs were comparable across treatment and placebo groups, and no serious TEAEs were reported during the study period.
- There were three severe TEAEs, and all of them were resolved or resolved with sequelae and were not related to tigulixostat.
"These results and the observed safety profile support dose-finding of tigulixostat and the continued development of tigulixostat in gout patients with hyperuricemia," the authors conclude.
Reference:
ABSTRACT NUMBER: L05. Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751